和肽素在急重症患者诊治中的应用进展

Progress in the application of copeptin in the diagnosis and treatment of acute and severe patients

和肽素(copeptin)于1972年由Holwerda发现[1],是神经垂体分泌的、与精氨酸升压素(arginjne-vasopressin,AVP)同源的糖基化肽,与精氨酸升压素等摩尔释放[2]。相关研究表明,在急性心力衰竭(AHF)、急性心肌梗死(AMI)、慢性阻塞性肺疾病急性加重(AECOPD)及脓毒症等急重症中,血浆和肽素水平明显升高,并与患者的病情、诊断及预后明显相关。本文简要综述和肽素在急重症患者诊治中的应用及其进展。

Copeptin is a glycosylation peptide secreted by the pituitary gland and homologous to arginine vasopressin.Its plasma level changes in the occurrence and development of acute and severe diseases such as myocardial ischemia,heart failure and sepsis.It has certain implications for the diagnosis,evaluation and prognosis of acute and severe diseases.And it is expected to become a new biological marker for clinical evaluation of acute and severe diseases.